Pharma news
Pharma
The German Court of Appeal has ruled that Indianapolis-based Eli Lilly’s European “vitamin regimen” patent for lung cancer injection Alimta would not be infringed by Actavis’s generic version. 9 March 2015
Asia
As India appears to forge closer trade relations with the US, will the country introduce a data exclusivity legal provision and what impact would this have? LSIPR investigates. 5 March 2015
Americas
Law firm Fried, Frank, Harris, Shriver & Jacobson has added a life sciences specialist to its intellectual property litigation practice. 5 March 2015
Asia
The battle between pharmaceutical and generics companies in India is once again in the spotlight, with a decision pending on another compulsory licence. The players this time are Novartis and Cipla, with the former already having drawn first blood. LSIPR investigates. 3 March 2015
Americas
The FDA could approve the US’s first biosimilar product any day now. But is the country ready for the wave of biosimilar applications that
will surely follow, and how quickly can these cut-price drugs come to market? LSIPR reports. 3 March 2015
Americas
AstraZeneca has closed a deal that will see it acquire the rights to Actavis’s branded respiratory drugs business in the US and Canada, it was announced today. 3 March 2015
Pharma
The English High Court has ordered the country’s National Health Service to issue guidance to medical professionals so that they prescribe Pfizer’s branded product Lyrica—not the generic version—for neuropathic pain. 3 March 2015
Americas
Which patented drugs are losing their market exclusivity in 2015, and how will their makers cope? LSIPR takes a look at five of the biggest drugs to lose patent protection in the US this year. 3 March 2015
Americas
Swiss pharmaceutical company Novartis can buy London-based GlaxoSmithKline’s portfolio of cancer drugs after it agreed to meet certain conditions set by the US Federal Trade Commission, the agency has said. 24 February 2015
Americas
Pharmaceutical companies Teva, Momenta, Mylan and Sandoz have asked the US Court of Appeals for the Federal Circuit for an expedited ruling on the validity of Teva’s patent covering its Copaxone drug. 23 February 2015